Reviewer's report

**Title:** Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells

**Version:** 2  **Date:** 28 November 2012

**Reviewer:** xiao-li Du

**Reviewer's report:**

The manuscript entitled “Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells” by Dr. Pan et al. studied the antitumor activity of YM155, an inhibitor of survivin, on SK-NEP-1 Wilms tumor cells, and analyzed the differential gene expression profile in YM155 treated or control cells by using Real-time PCR array. The data suggested that Y155 treatment could inhibit cell proliferation, induce apoptosis and decrease cell growth in vivo. This study is well designed, the charts and tables are clear and the conclusion is reasonable. This article can be accepted with minor revision. Here are the comments:

**Minor Essential Revisions**

1. In Figure 2A and 2B, there is no statistical analysis on both of the apoptosis and cell cycle data.

**Discretionary Revisions**

1. Why only Sk-NEP-1 cells were selected as the target cells of YM155? Did the author ever test the response of other Wilms tumor cell lines to YM155?
2. In table 1 and 2, some genes were shown to be differentially expressed between the untreated and treated groups with YM155 by using Real-time PCR array. Is there any validation experiment that has been done? The author could consider working on some of the dys-regulated genes in their future study.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests.